Study Overview: This study explores the effects of two drugs, vobramitamab duocarmazine and lorigerlimab, on advanced solid tumors. Solid tumors are abnormal growths of tissue that may spread to different parts of the body. The study checks how safe these drugs are, how well they work, and their effects on the body. It involves people with certain cancers like prostate, melanoma, and ovarian cancer.

Study Plan: Participants receive the drugs every 4 weeks for up to 2 years. Tumor checks happen every 8 weeks for the first 6 months, then every 12 weeks. Safety is closely monitored throughout.

Eligibility: To join, participants must have certain types of advanced cancer, have tried other approved treatments, and have a tumor sample available. They should also be healthy enough to participate and agree to use contraception.

• Duration: Up to 2 years with regular check-ups.
• Participation: Requires tumor samples and travel for assessments.
• Risks: Potential side effects include immune-related issues and drug reactions.